Literature DB >> 9915777

Local overexpression of thrombomodulin for in vivo prevention of arterial thrombosis in a rabbit model.

J M Waugh1, E Yuksel, J Li, M D Kuo, M Kattash, R Saxena, R Geske, S N Thung, S M Shenaq, S L Woo.   

Abstract

-Endothelial thrombomodulin plays a critical role in hemostasis by binding thrombin and subsequently converting protein C to its active form, a powerful anticoagulant. Thrombomodulin thus represents a central mechanism by which patency is maintained in normal vessels. However, thrombomodulin expression decreases in perturbed endothelial cells, predisposing to thrombotic occlusion. An adenoviral construct expressing thrombomodulin (Adv/RSV-THM) was created and functionally characterized in vitro and in vivo. The impact of local overexpression of thrombomodulin on in vivo thrombus formation was subsequently examined in a stasis/injury model of arterial thrombosis. The construct prevented arterial thrombosis formation in all animals, while viral and nonviral controls typically developed occluding thrombi. By histological analysis, nonviral controls exhibited intravascular thrombus occluding a mean of 70.52+/-3.72% of available lumen, while viral controls reached 86. 85+/-2.82% thrombotic occlusion; in contrast, Adv/RSV-THM reduced thrombosis to 28.61+/-3.31% of lumen in cross section. No significant intima-to-media ratio was observed in the thrombomodulin group relative to controls. Local infiltration of granulocytes and macrophages significantly decreased in the Adv/RSV-THM group relative to controls, while neutrophilic infiltration increased in viral controls relative to nonviral controls. This construct thus offers a viable technique for promoting a locally thromboresistant small-caliber artery, without the inflammatory damage that has limited many other adenoviral applications.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9915777     DOI: 10.1161/01.res.84.1.84

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  13 in total

Review 1.  Gene therapy for vein graft disease.

Authors:  D G Cable; H V Schaff
Journal:  Curr Cardiol Rep       Date:  2001-01       Impact factor: 2.931

2.  Genomic profiling of host responses to Lassa virus: therapeutic potential from primate to man.

Authors:  Juan C Zapata; Maria S Salvato
Journal:  Future Virol       Date:  2015-03-13       Impact factor: 1.831

3.  Patient-derived endothelial progenitor cells improve vascular graft patency in a rodent model.

Authors:  J D Stroncek; L C Ren; B Klitzman; W M Reichert
Journal:  Acta Biomater       Date:  2011-09-06       Impact factor: 8.947

Review 4.  Thrombomodulin and its role in inflammation.

Authors:  Edward M Conway
Journal:  Semin Immunopathol       Date:  2011-07-31       Impact factor: 9.623

Review 5.  Cardiovascular gene delivery: The good road is awaiting.

Authors:  L P Brewster; E M Brey; H P Greisler
Journal:  Adv Drug Deliv Rev       Date:  2006-07-07       Impact factor: 15.470

6.  In vitro functional testing of endothelial progenitor cells that overexpress thrombomodulin.

Authors:  John D Stroncek; Yujing Xue; Nabila Haque; Jeffrey H Lawson; William M Reichert
Journal:  Tissue Eng Part A       Date:  2011-05-25       Impact factor: 3.845

7.  Vein wall re-endothelialization after deep vein thrombosis is improved with low-molecular-weight heparin.

Authors:  Daria K Moaveni; Erin M Lynch; Cathy Luke; Vikram Sood; Gilbert R Upchurch; Thomas W Wakefield; Peter K Henke
Journal:  J Vasc Surg       Date:  2008-03       Impact factor: 4.268

8.  Anchoring fusion thrombomodulin to the endothelial lumen protects against injury-induced lung thrombosis and inflammation.

Authors:  Bi-Sen Ding; Nankang Hong; Melpo Christofidou-Solomidou; Claudia Gottstein; Steven M Albelda; Douglas B Cines; Aron B Fisher; Vladimir R Muzykantov
Journal:  Am J Respir Crit Care Med       Date:  2009-04-02       Impact factor: 21.405

9.  Gene therapy for atherosclerosis and atherosclerosis-related diseases.

Authors:  T Pakkanen; S Ylä-Herttuala
Journal:  Curr Atheroscler Rep       Date:  1999-09       Impact factor: 5.967

10.  Gene Therapy for Cardiovascular Disease.

Authors:  Kate L. Dishart; Lorraine M. Work; Laura Denby; Andrew H. Baker
Journal:  J Biomed Biotechnol       Date:  2003
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.